Chlorzoxazone reduced the paracetamol-induced toxicity via competitive inhibition of CYP2E1-mediated metabolism

被引:1
|
作者
Pingili, Ravindra Babu [1 ]
Vemulapalli, Sridhar [2 ,3 ]
Gadamsetty, Manideep V. V. N. [3 ]
Presingu, Divya [3 ]
Katuri, Ruthvik [3 ]
Rachamsetty, Vijayalakshmi [3 ]
Kilaru, Naveen Babu [3 ]
机构
[1] SVKMs NMIMS, Sch Pharm & Technol Management, Shirpur 425405, Maharashtra, India
[2] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA
[3] KVSR Siddhartha Coll Pharmaceut Sci, Dept Pharmaceut & Pharmaceut Biotechnol, Vijayawada 520010, Andhra Pradesh, India
关键词
N-Acetyl-p-benzoquinoneimine; Chlorzoxazone; Paracetamol; Hepatotoxicity; Nephrotoxicity; INDUCED LIVER-INJURY; P-GLYCOPROTEIN; CYTOCHROME P4502E1; WISTAR RATS; IN-VITRO; ACETAMINOPHEN HEPATOTOXICITY; PHARMACOKINETIC INTERACTION; ETHANOL; CYP2E1; COMBINATION;
D O I
10.1186/s43094-023-00484-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundDrug metabolism is crucial to attaining the therapeutic index of any drug. The metabolism and elimination of the drugs are governed mainly by P-glycoprotein (P-gp) and Cytochrome P450 (CYP). Paracetamol is mostly used as analgesic and antipyretic agent. The metabolism of paracetamol is primarily via Glucuronidation and sulphation at therapeutic doses. About 5-10% of paracetamol is metabolized via CYP mediated pathway. Cytochrome P450 2E1 (CYP2E1) is primarily responsible for forming a toxic metabolite of paracetamol called N-acetyl-p-benzoquinoneimine (NAPQI). Even at therapeutic doses, long-term usage of paracetamol leads to the hepatic and nephrotoxicity because of NAPQI. Several in-vitro and in-vivo studies conducted by different research groups and reported that chlorzoxazone is a substrate and inhibitor of CYP2E1. However, the effect of chlorzoxazone on the paracetamol (CYP2E1 substrate) metabolism via the CYP2E1 has not yet been reported. This study investigated the effect of chlorzoxazone on the CYP2E1-mediated metabolism of Paracetamol and NAPQI formation in Wistar rats.ResultsFor 15 days, animals were orally administered with Paracetamol (300 mg/kg) with and without Silymarin (100 mg/kg) (standard CYP2E1 inhibitor) and Chlorzoxazone (50 and 100 mg/kg). Analysis was performed using RP-HPLC on the 15th day to determine paracetamol and NAPQI concentration in the plasma. Paracetamol combination with chlorzoxazone (50 and 100 mg/kg) showed a dose-dependent increase in the AUC(0-infinity) and the peak plasma concentration (C-max) of Paracetamol and a dose-dependent decrease of AUC(0-infinity) and C-max of NAPQI compared to paracetamol control (p < 0.001). Chlorzoxazone significantly decreased the elevated liver and renal markers compared to paracetamol control. Simultaneously, Hepatic and nephrotic tissue studies showed that compared to the paracetamol control group, the combination of chlorzoxazone significantly ameliorated paracetamol-induced hepatotoxicity and nephrotoxicity.ConclusionFinally, this study revealed that paracetamol in combination with chlorzoxazone led to a significant decrease in the plasma levels of NAPQI and enhanced absorption of paracetamol in rats via the inhibition of CYP2E1- mediated metabolism. In addition, chlorzoxazone significantly ameliorated paracetamol-induced hepatotoxicity and nephrotoxicity.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] VITAMIN C DEFICIENCY EXACERBATES ALCOHOLIC LIVER INJURY VIA IMPAIRED REGULATION OF CYP2E1-MEDIATED PATHWAY
    Baek, Su-Min
    Lee, Seoung-Woo
    Lee, A-Rang
    Bang, Jun-Sun
    Kim, Tae-Un
    Choi, Seong-Kyoon
    Kim, Tae-Hwan
    Park, Sang-Joon
    Jeong, Kyu-Shik
    Park, Jin-Kyu
    HEPATOLOGY, 2019, 70 : 837A - 837A
  • [22] Application of an Updated Physiologically Based Pharmacokinetic Model for Chloroform to Evaluate CYP2E1-Mediated Renal Toxicity in Rats and Mice
    Sasso, Alan F.
    Schlosser, Paul M.
    Kedderis, Gregory L.
    Genter, Mary Beth
    Snawder, John E.
    Li, Zheng
    Rieth, Susan
    Lipscomb, John C.
    TOXICOLOGICAL SCIENCES, 2013, 131 (02) : 360 - 374
  • [23] Involvement of hepatic stellate cell cytoglobin in acute hepatocyte damage through the regulation of CYP2E1-mediated xenobiotic metabolism
    Teranishi, Yuga
    Matsubara, Tsutomu
    Krausz, Kristopher W.
    Le, Thi T. T.
    Gonzalez, Frank J.
    Yoshizato, Katsutoshi
    Ikeda, Kazuo
    Kawada, Norifumi
    LABORATORY INVESTIGATION, 2015, 95 (05) : 515 - 524
  • [24] Phenobarbital induces monkey brain CYP2E1 protein but not hepatic CYP2E1, in vitro or in vivo chlorzoxazone metabolism
    Lee, Anna M.
    Joshi, Meenal
    Yue, Jiang
    Tyndale, Rachel F.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 552 (1-3) : 151 - 158
  • [25] Comment on: "Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen"
    Reith, David M.
    CLINICAL PHARMACOKINETICS, 2018, 57 (07) : 895 - 896
  • [26] Comment on: “Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen”
    David M. Reith
    Clinical Pharmacokinetics, 2018, 57 : 895 - 896
  • [27] TRPV4 prevents tissue injury in diseased fatty liver by blocking CYP2E1-mediated redox-toxicity via Kupffer cell-induced nitric oxide production
    Seth, Ratanesh K.
    Dattaroy, Diptadip
    Chandrashekaran, Varun
    Das, Suvarthi
    Alhasson, Firas
    Bonini, Marcelo G.
    Michelotti, Gregory A.
    Nagarkatti, Mitzi
    Nagarkatti, Prakash
    Diehl, Anna Mae
    Bell, Phillip D.
    Liedtke, Wolfgang B.
    Chatterjee, Saurabh
    HEPATOLOGY, 2016, 64 : 793A - 794A
  • [28] Opposite action of S-adenosyl methionine and its metabolites on CYP2E1-mediated toxicity in pyrazole-induced rat hepatocytes and HepG2 E47 cells
    Wu, DF
    Cederbaum, AI
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2006, 290 (04): : G674 - G684
  • [29] Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver
    Howard, LA
    Micu, AL
    Sellers, EM
    Tyndale, RF
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 299 (02): : 542 - 550
  • [30] Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers
    Eap, CB
    Schnyder, C
    Besson, J
    Savary, L
    Buclin, T
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) : 52 - 57